Observational studyMedicine2025
Real-world safety profile of the diphtheria, tetanus, and acellular pertussis combined vaccine: A study in Huzhou from 2020 to 2024.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adverse reactions following upper arm vs. buttock DTaP vaccination in children: A retrospective observational study in Wuxi, China, 2020-2024.Human vaccines & immunotherapeutics · 2026Observational
- Comparative analysis of adverse events following immunization with DTaP vaccine in children before and after immunization schedule adjustment.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to evaluate the safety profile of the diphtheria, tetanus, and acellular pertussis combined vaccine (DTaP) based on real-world data from 2020 to 2024 in Huzhou city and provided data support for the adjustment of DTaP immunization strategy. The data of adverse events following immunization (AEFI) and vaccination information were collected from National Adverse Event Following Immunization Surveillance System (NAEFISS) in Huzhou city from 2020 to 2024 for a descriptive epidemiological analysis. This study used the reporting odds ratio (ROR) was for anomalous signal assessment. A total of 483 AEFI of DTaP vaccine were reported in Huzhou city from 2020 to 2024, the reported rate of AEFI was 15.87/10,000 doses. The reporting rate of AEFI showed an increasing trend from 2020 to 2024 (Z = 2.314, P = .021). There was no significant changes in the reporting rates of rare vaccine reactions (Z = -0.943, P = .346). There were 7 cases of allergic rash (0.23/10,000 doses), 1 case of urticaria (0.03/10,000 doses), 1 case of angioedema (0.03/10,000 doses). The most common AEFI reported was redness with 373 cases (12.25/10,000 doses), followed by induration (213 case, 7.00/10,000 doses). A positive signal association between DTaP and adverse events such as redness (ROR-1.96SE: 2.56) (standard error [SE]), induration (ROR-1.96SE: 2.07) and crying (ROR-1.96SE: 1.15) was found. The present findings supported that the DTaP vaccine was generally well tolerated as this study did not identify any new/unexpected safety concern during a 5-year time period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.